Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.

× No keyword cloud information.

24 in total

1. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.

Authors: S E Langabeer; F Ni Ainle; E Conneally; M Lawler
Journal: Ir J Med Sci Date: 2007-04-18 Impact factor: 1.568

2. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.

Authors: Youwen Qin; Xiaorui Wang; Chuxian Zhao; Chun Wang; Yining Yang
Journal: Int J Hematol Date: 2015-05-22 Impact factor: 2.490

Review 3. Somatic Mutations and Clonal Hematopoiesis: Unexpected Potential New Drivers of Age-Related Cardiovascular Disease.

Authors: José J Fuster; Kenneth Walsh
Journal: Circ Res Date: 2018-02-02 Impact factor: 17.367

Review 4. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors: David P Steensma
Journal: J Mol Diagn Date: 2006-09 Impact factor: 5.568

5. Clinical significance of circulating microparticles in Ph^- myeloproliferative neoplasms.

Authors: Wenjuan Zhang; Jiaqian Qi; Shixiang Zhao; Wenhong Shen; Lan Dai; Wei Han; Man Huang; Zhaoyue Wang; Changgeng Ruan; Depei Wu; Yue Han
Journal: Oncol Lett Date: 2017-06-22 Impact factor: 2.967

6. JAK2 V617F and the evolving paradigm of polycythemia vera.

Authors: Robert T Means
Journal: Korean J Hematol Date: 2010-06-30

7. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.

Authors: Marina Marchetti; Carmen J Tartari; Laura Russo; Marina Panova-Noeva; Annamaria Leuzzi; Alessandro Rambaldi; Guido Finazzi; Barry Woodhams; Anna Falanga
Journal: Am J Hematol Date: 2013-11-20 Impact factor: 10.047

8. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Authors: Zbigniew Rudzki; Tomasz Sacha; Anastazja Stój; Sylwia Czekalska; Małgorzata Wójcik; Aleksander B Skotnicki; Barbara Grabowska; Andrzej Zduńczyk; Krzysztof Okoń; Jerzy Stachura
Journal: Int J Hematol Date: 2007-08 Impact factor: 2.490

9. Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.

Authors: Roberto Latagliata; Angela Rago; Antonio Spadea; Cristina Santoro; Ida Carmosino; Massimo Breccia; Laura Napoleone; Angelo Fama; Francesca Biondo; Paola Volpicelli; Federico Vozella; Caterina Stefanizzi; Maria Concetta Petti; Giuliana Alimena; Maria Gabriella Mazzucconi
Journal: Int J Hematol Date: 2009-08-22 Impact factor: 2.490

10. Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.

Authors: Young-Uk Cho; Hyun-Sook Chi; Eun-Hye Lee; Seongsoo Jang; Chan-Jeoung Park; Eul-Ju Seo
Journal: Int J Hematol Date: 2008-12-18 Impact factor: 2.490